Clinical Trials Directory

Trials / Unknown

UnknownNCT05143736

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Patients With Sepsis: a Prospective, Multicentered, Diagnostic Trial

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Zhujiang Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

In this prospective, multicentered , diagnostic trial, nasal and fecal specimens will collected from patients with sepsis in two critical care units(ICU) at the enrollment day ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and sequenced to determined the characteristics of gut microbiota and nasal microbiota. Finally, the characteristics of gut microbiota and nasal microbiota combined clinical information will be used to construct a prediction model to predict the prognosis of sepsis.

Detailed description

Background: Sepsis should be defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality, and its total mortality is 10% to 52%. In sepsis, it is not clear sufficiently about the relationship between intestinal and nasal microbiota character and the development of the sepsis.The study aim to construct a prediction model to predict the prognosis and development of sepsis. Purpose: 1. To construct a prediction model using nasal and gut microbiota combined with clinical events to predict the prognosis of patients with sepsis and development of sepsis. 2. Analyze the characteristics of nasal and gut microbiota in patients with sepsis using microbiology. Methods: nasal and fecal specimens will collected from patients with sepsis in two critical care units(ICU) at the enrollment day ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and sequenced to determined the characteristics of gut microbiota and nasal microbiota. Meanwhile, some related clinical information also will be collected,including demographic characteristics, comorbidities, infection site, results of the microbiology experiments, vital signs, invasive tubing indwelling at enrollment,combined medication,the requirement of organ function support, laboratory indexing, sequential organ failure assessment score and Acute Physiology and Chronic Health Evaluation score. Finally, the characteristics of gut microbiota and nasal microbiota combined the clinical information will be used to construct a prediction model to predict the prognosis of sepsis. The primary outcome is the 28-day all-cause mortality. The secondary outcomes are the incidence of septic shock, the incidence of persistent inflammation- immunosuppression catabolism syndrome and the 90-day all-cause mortality.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTgut and nasal microbiota detectionThe nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.

Timeline

Start date
2022-01-10
Primary completion
2024-12-31
Completion
2025-01-31
First posted
2021-12-03
Last updated
2024-03-19

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05143736. Inclusion in this directory is not an endorsement.

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients (NCT05143736) · Clinical Trials Directory